Vanguard Global Advisers
CYTK icon

Vanguard Global Advisers’s Cytokinetics CYTK Stock Holding History

Vanguard Global Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19M Buy
60,957
+5,774
+10% +$415K ﹤0.01% 779
2026
Q1 		$3.64M Buy
+55,183
New +$3.51M ﹤0.01% 883

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's CYTK Position: Q2 2026 in Review

Vanguard Global Advisers increased its Cytokinetics (CYTK) stake by 10% in Q2 2026, buying an estimated $415K and bringing the position to 60,957 shares worth $5.19M. The position accounts for ﹤0.01% of the portfolio, ranked #779.

Vanguard Global Advisers first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Global Advisers held 60,957 shares of Cytokinetics worth $5.19M as of Q2 2026.
  • Vanguard Global Advisers bought 5,774 Cytokinetics shares in Q2 2026, an estimated $415K.
  • Cytokinetics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #779 holding.
  • Vanguard Global Advisers first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 475 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.